Thrombolytic therapy with continuous infusion of streptokinase has been shown to be an effective form of treatment in certain thrombo-embolic conditions. This paper presents details of methods which have proved satisfactory for laboratory control of the treatment of 24 patients. Clinical results are reported elsewhere (Hawkey and Howell, 1964) .
Streptokinase can be given either systemically by an intravenous drip in order to induce a high level of activator throughout the circulation, or by local infusion into an occluded artery so that relatively large amounts of activator can be delivered close to the thrombus with minimal activation of the plasminogen elsewhere. Whichever route is used, intravascular thrombolysis ultimately depends on the maintenance of a high local concentration of activator in order to activate the plasminogen within the thrombus . The presence of activator in the general circulation does, however, result in the production of plasmin and, although this is to some extent inactivated by circulating antiplasmins, some plasmin remains capable of degrading certain plasma clotting factors. During infusions of activator this systemic effect may impair blood coagulation: tests should be carried out at frequent intervals to assess the concentration of activator and to screen for the development of any defect of haemostasis.
Streptokinase is antigenic and human blood contains antibodies, present as a result of incidental streptococcal infections. The anti-streptokinase antibody level varies considerably amongst individuals and therefore it is necessary to carry out a titration before the infusion is begun in order to calculate the neutralizing dose for a given case. In systemic therapy a loading dose of streptokinase large enough to overcome the antibodies present must be given before the required effect will be apparent in the general circulation. When streptokinase is given locally, however, the antibodies will Received for publication 12 February 1964. neutralize it in the general circulation, thus limiting systemic activation; in this situation an initial knowledge of the antibody level permits estimation of the amount of streptokinase which can be given without the accumulation of free streptokinase in the circulating blood.
Although (Flute, 1960) which could influence the result of this test.
Streptokinase of the type to be used for infusion is diluted with physiological saline to give a solution containing 5,000 units/ml. All streptokinase dilutions are made up immediately before use and kept in an ice bath. A series of dilutions is prepared as shown in Table I . Of each dilution, 0 05 ml. is pipetted into a duplicate series of tubes in an ice bath and, using a graduated polythene pipette, 0-5 ml. chilled E.D.T.A. plasma is added to each tube, beginning with the saline control and the lowest concentration of streptokinase. Immediately, 01 ml. of thrombin (50 units/ml.) is added to each tube, the tubes shaken and transferred to a water bath at 37°C. A stop watch is started as thrombin is added to the first tube. The tubes are examined after one Chilled citrated plasma, 0-5 ml., is added to 9 ml. ice-cold distilled water acidified with acetic acid to give a final pH of 5-3. After mixing, the euglobulin precipitate is obtained by centrifuging immediately at 4°C. for five minutes at 1,688 g (3,000 r.p.m.). The supernatant is discarded and the precipitate re-dissolved in 0-5 ml. phosphate buffer. Then 0-4 ml. of the re-dissolved precipitate is clotted in a glass tube at 37°C. by adding 0 1 ml. thrombin (50 units/ml. During systemic fibrinolytic states the prothrombin time becomes prolonged due to the breakdown of plasma clotting factors and the anticoagulant effects of fibrinogen breakdown products. Assays of factors V, VII, and X on plasma samples collected during infusion confirm that no gross reduction of these factors occurs while the prothrombin activity is greater than 25 %.
Thrombin times Thrombin solution, 0-2 ml., is added to 0-2 ml. of citrated plasma at 37°C. and the clotting time recorded.
During sustained fibrinolytic activity in vivo the thrombin clotting time is influenced by two factors; first the reduction in circulating fibrinogen due to fibrinogenolysis by free plasmin. and secondly, by the 'antithrombin' effect of accumulating fibrinogen breakdown products (Niewiarowski and Kowalski, 1958; Fletcher, et al., 1959b) . In order to assess each of these effects, tests are carried out using two different strengths of thrombin, namely, a solution containing 50 N.I.H. units/ml. to give an indication of the fibrinogen level and a weaker solution containing 5 units/ml. which is sensitive to the presence of antithrombin activity. The normal range for these tests is: An increase in the strong thrombin time of more than five seconds indicates a reduction in the fibrinogen level to less than 100 mg./100 ml. A lengthening of the weak thrombin time to 100 seconds or more is usually accompanied by a deterioration in the quality of the clot probably due to interference of fibrin polymerization by products of fibrinogen breakdown. The weak thrombin test often remains prolonged after the fibrinogen level has returned to normal, indicating that the clearance rate of fibrinogen breakdown products is slow; this fact should be borne in mind if heparin is to be used directly after an infusion of streptokinase.
FIBRINOJEN ESTIMATION Fibrinogen should be measured by its ability to clot, as the presence of fibrinogen breakdown products may affect the results of immunological and precipitation methods. A modification of the method of Ratnoff and Menzie (1951) has been used in the present study.
Citrated plasma is mixed with E.A.C.A. as soon as possible after collection and stored at -350C. For the test, plasma is thawed at 37°C., and 0-2 ml. plasma is mixed with 1 ml. of saline/E.A.C.A. and approximately 0 5 ml. of crushed, acid-cleaned, pyrex glass and clotted with 0 05 ml. thrombin (500 units/ml.). After 30 minutes at room temperature the tubes are shaken vigorously to break up the clots and collect the fibrin on the crushed glass. The mixture of glass and fibrin is washed twice in saline/E.A.C.A. Then 4 ml. of 1 % NaOH is added and the tubes placed in a boiling bath for 10 minutes to hydrolyse the fibrin. When cool, 1-2 ml. of 20% Na2CO3 and 0-4 ml. Folin Ciocalteau reagent is added and after 10 minutes, during which time the colour develops, a 1 in 4 dilution of the supernatant is made in distilled water. Colour is read in a Unicam SP1500 spectrophotometer at a wavelength of 650 m,u against a thrombin blank set up in the same way as the tests but with no plasma.
A calibration curve is prepared from a standard tyrosine solution; this is used to convert spectrophotometer readings to milligrams tyrosine, when mg. tyrosine x 16-4 = mg. fibrinogen/100 ml. plasma. Correction must be made for dilution of the original plasma by citrate.
PLASMINOGEN ESTIMATION This is carried out by the caseinolytic assay described by Remmert and Cohen (1949) as modified by Alkjaersig et al. (1959a) .
The tests are set up in duplicate. Chilled citrated plasma, 0-5 ml., is added to 0 5 ml. N/6 HCI and after 15 minutes at room temperature the acid is neutralized by the addition of 0 5 ml. N/6 NaOH. The FACTOR X ASSAY By the method of Denson (1961) using commercially prepared factor X substrate plasma.
DISCUSSION
By adjustment of the infusion rate according to the results of the tests described, it is possible to maintain the necessary balance between an effective level of activator and overdosage. Although streptokinase has been the activator in the present series, these tests can also be used for the control of urokinase infusions. The coagulation defect arising during thrombolytic therapy is due to the reduction of clotting factors by proteolysis and the accumulation of the products of fibrinogenolysis which interfere with fibrin polymerization. There is some evidence that slow activation of plasminogen results in higher levels of free plasmin than if plasminogen depletion is brought about rapidly by a large initial dose of activator. Therefore the possibility of inducing a coagulation defect exists in both systemic and local therapy although relatively smaller amounts of streptokinase are infused in the latter. In our experience this defect is only significant if there is a lesion such as a recent operation wound or an area of cerebral softening.
Should it be necessary to reverse the systemic effects of thrombolytic therapy the intravenous injection of epsilon-amino-caproic acid' will inhibit the action of streptokinase. The recommended dose of this drug which prevents the activation of plasminogen is 1 g./10 kg. body weight (Nilsson and Olow, 1962b) . The effects of the coagulation defect can then be controlled by infusion of fibrinogen and fresh frozen plasma or fresh blood.
